State Key Laboratory of Bioreactor Engineering & Shanghai Key Laboratory of Chemical Biology, School of pharmacy, East China University of Science and Technology, Shanghai, 200237, People's Republic of China.
Invest New Drugs. 2011 Aug;29(4):646-58. doi: 10.1007/s10637-010-9403-9. Epub 2010 Feb 24.
In the course of screening for novel anticancer compounds, B1 (N-(2-(Dimethylamino)ethyl)-2-aminothiazonaphthalimide), a novel naphthalimide-based DNA intercalator, was generated as a new anticancer candidate. For the first time, our investigation demonstrates that B1 inhibited the growth of HeLa cells by the induction of cell cycle arrest and apoptosis. Analysis of flow cytometry and western blots of HeLa cells treated with B1 revealed an appreciable cell cycle arrest and apoptotic induction in dose and time-dependent manner via the p53-dependent pathway. Furthermore, the release of cytochrome c from mitochondria was detected using confocal microscopy in HeLa cells treated with B1. Accordingly, these data demonstrate that the anticancer activity of B1 is associated with the activation of p53 and the release of cytochrome c, which suggest that B1 might have therapeutic potential against cervix carcinoma as an effective lead compound.
在筛选新型抗癌化合物的过程中,B1(N-(2-(二甲氨基)乙基)-2-氨基噻唑并萘酰亚胺)作为一种新型的萘酰亚胺类 DNA 嵌入剂被发现是一种新的抗癌候选物。我们的研究首次表明,B1 通过诱导细胞周期停滞和细胞凋亡来抑制 HeLa 细胞的生长。通过流式细胞术和 Western blot 分析,B1 处理的 HeLa 细胞以剂量和时间依赖的方式通过 p53 依赖性途径表现出明显的细胞周期停滞和凋亡诱导。此外,使用共聚焦显微镜检测到 B1 处理的 HeLa 细胞中线粒体细胞色素 c 的释放。因此,这些数据表明,B1 的抗癌活性与 p53 的激活和细胞色素 c 的释放有关,这表明 B1 可能作为一种有效的先导化合物,具有治疗宫颈癌的潜力。